Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Jenkin

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
JCI Insight|February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne Ogbe, Matthew Pace, Mustapha Bittaye, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell|January 26, 2022
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
JCI Insight|February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne Ogbe, Matthew Pace, Mustapha Bittaye, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell|January 26, 2022
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 3